Womens Health Investment Outlook 2026

Proof points of investor returns across women’s health BOX 1 The following cases illustrate what is possible and scalable when more capital flows into the women’s health space. Diagnostics scale story – reimbursement-backed growth A leading diagnostics company in prenatal and oncology testing has delivered approximately 30% annual growth, 60%-plus gross margins and recurring demand anchored in clinical guidelines and payer coverage. Investor signal: Reimbursement and standard-of- care adoption are creating defensible, predictable revenue streams, positioning diagnostics as a scalable subsector in women’s health. Strategic exit precedent – $3.7 billion acquisition underscores value A global strategic acquirer purchased a pelvic- health medtech company for approximately $3.7 billion, highlighting the value placed on women’s health solutions addressing large, underpenetrated markets. Investor signal: Attractive exit multiples demonstrate that large strategic companies are actively expanding into women’s health.PE leaning in – institutional appetite emerging A diversified women’s health leader in diagnostics and breast health received a definitive agreement to be acquired, which placed the company’s enterprise value at approximately $18.3 billion. Investor signal: Even without a completed transaction, the bid indicates the rising institutional appetite for large cash-generating platforms and confirms women’s health as a scalable, multibillion-dollar investment category. Biopharma investor returns – competitive public-to-private upside A biopharma focused on uterine fibroids and endometriosis delivered approximately 80% investor returns from IPO to a $1.7 billion all-cash acquisition. Investor signal: Biopharma assets addressing women-specific conditions are producing competitive exit multiples and liquidity events, comparable to broader biotech benchmarks.Example 1 Example 2Example 3 Example 4 To complement the investment landscape analysis, a review was conducted of the top 100 global healthcare companies by revenue across pharmaceuticals, medtech and diagnostics, to understand the extent and nature of their participation in women’s health (see Box 2). The findings show that, while some progress is emerging, women’s health remains a relatively underdeveloped strategic focus across the industry. Women’s Health Investment Outlook 17